CAR-engineered T cells that target B-cell maturation antigen (BCMA), CD138, CS1 glycoprotein antigen (SLAMF7), and light chains are being developed actively for the treatment of r/r MM. Here, TNFRSF17 is linked to Miyoshi myopathy.